“With SAVA, once the pullback has exhausted itself, it’s a strong buy,” we noted on July 29.
Since bottoming out around $65, the stock is back to $86.20 – and could refill its bearish gap around $140 with patience. In fact, if the company can continue to progress with its Alzheimer’s treatment, this stock could rocket well above $140, long-term.
Right now, in a clinical study funded by the National Institutes of Health (NIH), simufilam significantly improved all measured biomarkers in patients with Alzheimer’s disease following 6 months of open-label treatment, according to a company release. “Six months of simufilam treatment robustly improved brain biomarkers,” said Remi Barbier, President and CEO. “In this same study simufilam also improved cognition. These data suggest simufilam has potential to provide durable treatment effects for people living with Alzheimer’s.”
Also, we have to consider the Alzheimer’s market is massive.
“As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to 150 million by 2050. The annual global cost of dementia is now above $1 trillion, according to Alzheimer’s Disease International, a charitable organization,” as noted by Cassava Sciences.
Hopefully, those folks can finally get the treatment they desperately need.
